What This Apogee Insider Move Might Mean After a 247% Stock Run
Henderson's disposition included a 20,000-share open-market sale and a 75,046-share charitable gift.
Overview
Michael Thomas Henderson, Chief Executive Officer of Apogee Therapeutics, Inc. (NASDAQ:APGE), reported a disposition of 95,046 shares of common stock on July 8, 2026 and July 10, 2026, according to a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($133.63); post-transaction value based on July 10, 2026 market close ($133.65).
Details
Apogee Therapeutics is a clinical-stage biotechnology company headquartered in Waltham with a focused pipeline of biologic therapies addressing significant unmet medical needs in inflammatory and immunological disorders. The company's competitive strategy centers on the development of extended half-life monoclonal antibodies designed to enhance patient outcomes and treatment adherence. With a market capitalization of $8.2 billion and substantial recent equity appreciation, Apogee represents a high-growth biotech investment thesis dependent on successful clinical development and regulatory approval of its lead candidates.
Source
Originally published at www.fool.com.